End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?-Reference-Cited by-同舟云学术

End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?

Published:2024-06-18 Issue: Volume: Page:1-15
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Degtyarev Evgeny¹^ORCID,Bolaños Natacha²,Brody Joshua D³,Buchbinder Aby⁴,Buyse Marc⁵⁶,Fuchs Miriam¹,Halabi Susan⁷⁸,Hemmings Robert⁹,Masood Aisha⁴,Newsome Simon¹,Saxton Claire¹⁰,Warwick Lorna¹¹,Yateman Nigel A¹,Zuber Emmanuel¹

Affiliation:

1. Novartis Pharma, Basel, Switzerland

2. Lymphoma Coalition, Madrid, Spain

3. Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

4. Novartis Pharmaceuticals, East Hanover, NJ, USA

5. International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium

6. Interuniversity Institute for Biostatistics & Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium

7. Duke Clinical Research Institute, Durham, North Carolina, USA

8. Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA

9. CONSILIUM Salmonson & Hemmings, Woking, UK

10. Cancer Support Community, Washington, DC, USA

11. Lymphoma Coalition, Management, Mississauga ON, Canada

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2357537

Reference65 articles.

1. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint

2. FDA Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and biologics. December 2018. Available from: www.fda.gov/media/71195/download

3. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany

4. ICH Harmonised Guideline. E8(R1) General considerations for clinical studies. [updated 2021 Oct 06]. Available from: www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf

5. ICH Harmonised Guideline. E9(R1) Addendum on estimands and sensitivity analysis in clinical trials. [updated 2019 Nov 20]. Available from: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf